These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26117157)

  • 1. Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study.
    Harvey PD; Siu CO; Ogasa M; Loebel A
    Schizophr Res; 2015 Aug; 166(1-3):334-8. PubMed ID: 26117157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension.
    Harvey PD; Siu CO; Hsu J; Cucchiaro J; Maruff P; Loebel A
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1373-82. PubMed ID: 24035633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
    Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insight and Treatment Outcomes in Schizophrenia:
    Harvey PD; Siu CO; Loebel AD
    Innov Clin Neurosci; 2017 Dec; 14(11-12):23-29. PubMed ID: 29410934
    [No Abstract]   [Full Text] [Related]  

  • 5. Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia.
    Loebel AD; Siu CO; Cucchiaro JB; Pikalov AA; Harvey PD
    CNS Spectr; 2014 Apr; 19(2):197-205. PubMed ID: 24330860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.
    Meyer JM; Mao Y; Pikalov A; Cucchiaro J; Loebel A
    Int Clin Psychopharmacol; 2015 Nov; 30(6):342-50. PubMed ID: 26196189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study.
    Loebel A; Cucchiaro J; Xu J; Sarma K; Pikalov A; Kane JM
    Schizophr Res; 2013 Jun; 147(1):95-102. PubMed ID: 23583011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance, sedation and patient satisfaction in patients with schizophrenia: a randomised, double-blind, crossover study (eXtRa).
    Riedel M; Schmitz M; Østergaard PK; Ferrannini L; Franco MA; Alfano V; Vansvik ED
    Schizophr Res; 2015 Mar; 162(1-3):162-8. PubMed ID: 25592805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
    Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
    Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Citrome L
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
    Harvey PD; Ogasa M; Cucchiaro J; Loebel A; Keefe RS
    Schizophr Res; 2011 Apr; 127(1-3):188-94. PubMed ID: 21277745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of lurasidone in the treatment of agitation: A post hoc analysis of five short-term studies in acutely ill patients with schizophrenia.
    Allen MH; Citrome L; Pikalov A; Hsu J; Loebel A
    Gen Hosp Psychiatry; 2017 Jul; 47():75-82. PubMed ID: 28807142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia.
    Miller BJ; Pikalov A; Siu CO; Tocco M; Tsai J; Harvey PD; Newcomer JW; Loebel A
    Compr Psychiatry; 2020 Oct; 102():152195. PubMed ID: 32896775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recovery in bipolar depression: Post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study.
    Loebel A; Siu C; Rajagopalan K; Pikalov A; Cucchiaro J; Ketter TA
    J Affect Disord; 2015 Nov; 186():376-82. PubMed ID: 26363720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study.
    Loebel A; Silva R; Goldman R; Watabe K; Cucchiaro J; Citrome L; Kane JM
    J Clin Psychiatry; 2016 Dec; 77(12):1672-1680. PubMed ID: 27454547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression.
    Rajagopalan K; Meyer K; O'Day K; Denno M; Loebel A
    J Med Econ; 2015; 18(10):821-7. PubMed ID: 25985265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.
    Tandon R; Cucchiaro J; Phillips D; Hernandez D; Mao Y; Pikalov A; Loebel A
    J Psychopharmacol; 2016 Jan; 30(1):69-77. PubMed ID: 26645209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned.
    Cutler AJ; Tran-Johnson T; Kalali A; Aström M; Brecher M; Meulien D
    Psychopharmacol Bull; 2010; 43(4):37-69. PubMed ID: 21240151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.
    McEvoy JP; Citrome L; Hernandez D; Cucchiaro J; Hsu J; Pikalov A; Loebel A
    J Clin Psychiatry; 2013 Feb; 74(2):170-9. PubMed ID: 23473350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study.
    Stahl SM; Cucchiaro J; Simonelli D; Hsu J; Pikalov A; Loebel A
    J Clin Psychiatry; 2013 May; 74(5):507-15. PubMed ID: 23541189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.